Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

NCT ID: NCT01049217

Last Updated: 2021-01-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

377 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy of pregabalin compared to placebo in reducing neuropathic pain associated with HIV neuropathy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Based on DMC interim efficacy analysis results indicating a low probability for success the study was terminated on April 2, 2012; the termination was unrelated to any safety findings that could impact patient health.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active drug

Group Type EXPERIMENTAL

pregabalin

Intervention Type DRUG

Pregabalin 75 mg-300mg twice daily during the course of the study.

Control

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pregabalin

Pregabalin 75 mg-300mg twice daily during the course of the study.

Intervention Type DRUG

placebo

Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women, ages of 18 or greater
* Documented evidence of HIV-1 infection
* Documented diagnosis of HIV-associated Distal Symmetrical Polyneuropathy (DSP) with subjective sensory symptom of pain
* Pain starts in the feet

Exclusion Criteria

* Subject has untreated vitamin B12 deficiency (serum B12 level \<200 pg/ml) or if treated B12 deficiency -treatment is less than 6 months of B12 supplementation (injection or intranasal B12) prior to screening
* Diabetes mellitus requiring regular medical treatment (other than diet and exercise) or HbA1C \>6.9
* Subjects with peripheral neuropathic pain that is not associated with HIV infection; including subjects with conditions such as: Post Herpetic Neuralgia (PHN), Diabetic Peripheral Neuropathy (DPN), familial neuropathies; compression related neuropathy, radicular pain, other infection related neuropathies (eg, leprosy); neuropathy related to: metabolic abnormalities; nutritional factors; vascular insults; inflammation; autoimmune disease; and malignancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southwest Center for HIV/AIDS

Phoenix, Arizona, United States

Site Status

SW Center for HIV/AIDS

Phoenix, Arizona, United States

Site Status

Arizona Research Center

Phoenix, Arizona, United States

Site Status

AIDS Research Alliance of America

Los Angeles, California, United States

Site Status

Anthony Mills, MD, Inc.

Los Angeles, California, United States

Site Status

David Geffen School of Medicine at UCLA c/o NNAB

Los Angeles, California, United States

Site Status

Providence Clinical Research

North Hollywood, California, United States

Site Status

Desert Medical Group, Inc. dba Desert Oasis Healthcare Medical Group

Palm Springs, California, United States

Site Status

University of California San Diego

San Diego, California, United States

Site Status

Stanford University Medical Center

Stanford, California, United States

Site Status

Neuroscience Consultants, LLC.

Aventura, Florida, United States

Site Status

South Florida Medical Research

Aventura, Florida, United States

Site Status

The Kinder Medical Group

Miami, Florida, United States

Site Status

Wohlfeiler, Piperato & Associates, LLC

Miami Beach, Florida, United States

Site Status

Meridien Research

Tampa, Florida, United States

Site Status

AIDS Research Consortium of Atlanta

Atlanta, Georgia, United States

Site Status

Midtown Neurology, PC

Atlanta, Georgia, United States

Site Status

Neurology Specialists of Decatur Research Center

Decatur, Georgia, United States

Site Status

Rehabilitation Institute of Chicago

Chicago, Illinois, United States

Site Status

Mount Sinai School of Medicine

New York, New York, United States

Site Status

University of Toledo Medical Center

Toledo, Ohio, United States

Site Status

University of Toledo

Toledo, Ohio, United States

Site Status

University of Texas Physicians

Bellaire, Texas, United States

Site Status

Amelia Court HIV Research Clinic

Dallas, Texas, United States

Site Status

The University of Texas Medical School at Houston

Houston, Texas, United States

Site Status

Asistencia Cientifica de Alta Complejidad

Bogota, Cundinamarca, Colombia

Site Status

Centro Instituto de Investigaciones Fundación Universitaria Sanitas

Bogota, Cundinamarca, Colombia

Site Status

Riesgo de Fractura S.A

Bogotá, Cundinamarca, Colombia

Site Status

Instituto Colombiano para el Avance de la Medicina- Santander S.A.S. - ICAMEDIC Santander S.A.S

Bucaramanga, Santander Department, Colombia

Site Status

Instituto Dominicano de Estudios Virológicos - IDEV

Santo Domingo, , Dominican Republic

Site Status

Mahavir Hospital and Research Centre

Hyderabad, Andhra Pradesh, India

Site Status

Surakshaka Multispeciality Hospital

Hyderabad, Andhra Pradesh, India

Site Status

Infectious Disease Clinic

Ahmedabad, Gujarat, India

Site Status

Jaslok Hospital & Research Centre

Mumbai, Maharashtra, India

Site Status

Deenanath Mangeshkar Hospital and Research Centre

Pune, Maharashtra, India

Site Status

YR Gaitonde Centre for AIDS Research and Education

Chennai, Tamil Nadu, India

Site Status

Hospital Nacional Dos de Mayo

Lima, , Peru

Site Status

Hospital Nacional Guillermo Almenara Irigoyen

Lima, , Peru

Site Status

Katedra Chorob Zakaznych i Hepatologii UMK w Toruniu CM w Bydgoszczy

Bydgoszcz, , Poland

Site Status

Oddzial Diagnostyki i Terapii AIDS

Chorzów, , Poland

Site Status

Ponce School of Medicine-CAIMED Center

Ponce, PR, Puerto Rico

Site Status

Ponce School of Medicine - Practice Group

Ponce, PR, Puerto Rico

Site Status

Puerto Rico Clinical and Translational Research Consortium

Rio Piedras, PR, Puerto Rico

Site Status

Border Diabetic Centre

East London, Eastern Cape, South Africa

Site Status

MediSynergy

Port Elizabeth, Eastern Cape, South Africa

Site Status

Worthwhile Clinical Trials

Benoni, Gauteng, South Africa

Site Status

Toga Laboratory

Johannesburg, Gauteng, South Africa

Site Status

Drs Essack and Mitha

Johannesburg, Gauteng, South Africa

Site Status

University of Witwatersrand-Clinical HIV Research Unit (CHRU)

Johannesburg, Gauteng, South Africa

Site Status

Synexus SA Stanza Bopape Clinical Research Centre

Pretoria, Gauteng, South Africa

Site Status

Pretoria West Hospital

Pretoria West, Gauteng, South Africa

Site Status

Chris Hani Baragwanath Hospital, The Palliative Care Centre

Soweto, Gauteng, South Africa

Site Status

Dr J. Reddy's Surgery

KwaDukuza, KwaZulu-Natal, South Africa

Site Status

University of Cape Town

Cape Town, Western Cape, South Africa

Site Status

Synapta Clinical Research Centre

Durban, , South Africa

Site Status

Innovir Institute

Gauteng, , South Africa

Site Status

Mzansi Ethical Research Centre

Middelburg, , South Africa

Site Status

Be Part Yoluntu Centre

Paarl, , South Africa

Site Status

Paarl Research Center

Paarl, , South Africa

Site Status

Clinical Research Unit, University of Pretoria

Pretoria, , South Africa

Site Status

Department of Neurology

Tygerberg, , South Africa

Site Status

South East Asia Research Collaboration with Hawaii

Bangkok, , Thailand

Site Status

Neurology unit, Department of Medicine,

Bangkok, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Colombia Dominican Republic India Peru Poland Puerto Rico South Africa Thailand

References

Explore related publications, articles, or registry entries linked to this study.

Simpson DM, Rice AS, Emir B, Landen J, Semel D, Chew ML, Sporn J. A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy. Pain. 2014 Oct;155(10):1943-54. doi: 10.1016/j.pain.2014.05.027. Epub 2014 Jun 4.

Reference Type DERIVED
PMID: 24907403 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A0081244

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Adolescent Fibromyalgia Study
NCT01020474 COMPLETED PHASE4
Pregabalin and Orofacial Neuropathic Pain
NCT00852436 TERMINATED PHASE2